Digital Therapeutics Market by Application (Prevention (Prediabetes, Obesity), Care (Diabetes, CVD, CNS, CRD, Smoking Cessation, Musculoskeletal)), Sales Channel (B2C (Patient, Caregiver), B2B (Provider, Payer, Employer, Pharma)) - Global Forecast to 2021
The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021. The factors driving market growth include growing incidence of chronic diseases, rising focus on preventive healthcare, technological advancements, growing need to control healthcare costs, significant increase in venture capital investments, and the benefits of digital therapeutics. However, factors such as lack of awareness and access to digital therapeutics programs in developing countries, patient data privacy concerns, and resistance from traditional healthcare providers may restrain the digital therapeutics market growth.
North America dominates the digital therapeutics market, with the U.S. accounting for the major share and highest CAGR. This can be attributed to the growing incidence of chronic diseases, government initiatives to support technological advancements in digital therapeutics, gradually improving reimbursement structure for digital therapeutics solutions, and a growing influx of new startup companies in the market as a result of increasing investments in the digital therapeutics field. For instance, in July 2014, Proteus Digital Health (U.S.) secured an investment of USD 172 million from a list of institutional investors for the manufacturing and development of its digital medicine products. Furthermore, in January 2014, WellDoc, Inc. (U.S.) received USD 20 million from the Merck Global Health Innovation Fund (U.S.), which it used to commercialize its products in the U.S. Such investments are likely to spur the growth of the market in North America in the coming years.
The prominent players in the digital therapeutics market are Proteus Digital Health, Inc. (U.S.), Omada Health Inc. (U.S.), WellDoc Inc. (U.S.), Livongo Health (U.S.), Noom Inc. (U.S.), Ginger.io Inc. (U.S.), Propeller Health (U.S.), 2Morrow Inc. (U.S.), Canary Health Inc. (U.S.), and Mango Health, Inc. (U.S.).
To know about the assumptions considered for the study, download the pdf brochure
Scope of the Report
This report categorizes the digital therapeutics market into the following segments:
- Preventive
- l Prediabetes
- l Obesity
- Treatment/Care
- l Diabetes
- l Cardiovascular Diseases
- l Central Nervous System Disease
- Respiratory Diseases
- Musculoskeletal Diseases
- Smoking Cessation
- Medication Adherence
- Other Applications (Fitness and Wellness, Post-operative Care, Pregnancy and Parenting Management, and Personal Goal and Habit Platforms)
- B2C
- Patients
- Caregivers
- B2B
- Providers
- Payers
- Employers
- Pharmaceutical Companies
- Other Buyers (Wellness Centers, Fitness Centers, and Gyms)
- North America
- l U.S.
- l Canada
- Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe (RoE)
- Asia-Pacific
- Rest of the World (RoW)
Digital Therapeutics Market, by Application
Digital Therapeutics Market, by Sales Channel
Digital Therapeutics Market, by Region
Market Stakeholders:
- Digital therapeutics platform/software/app/therapy/program developers
- Healthcare institutions/providers (hospitals, medical groups, physician practices, community clinics, psychiatrists, and outpatient clinics)
- Healthcare insurance companies/payers
- Healthcare IT providers
- Venture capitalists
- Government agencies
- Market research and consulting firms
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company‘s specific needs.
The following customization options are available for the report:
Additional Company Profiling
- Company profiles for five additional companies.
The global digital therapeutics market is projected to reach USD 457.9 million by 2021 from USD 134.8 million in 2016, at a CAGR of 27.7% from 2016 to 2021. The growth in this market is majorly driven by government initiatives to increase focus on preventive healthcare, technological advancements in mobile healthcare, significant increase in venture capital investments, and benefits offered by digital therapeutics such as the ability to induce behavioral change (an important challenge in healthcare), user-friendliness and patient convenience, and improved drug compliance. On the other hand, lack of awareness and access to digital therapeutics programs in developing countries, patient data privacy concerns, and resistance from traditional healthcare providers are the major factors limiting the growth of the market to a certain extent.
B2B segment is expected to grow at the highest CAGR during the forecast period
Based on sales channel, the digital therapeutics market is segmented into business to customer (B2C) and business to business (B2B). In 2016, the B2B segment is estimated to account for the largest share along with the highest CAGR of the digital therapeutics market. There is a growing awareness among providers, payers, and employers about the benefits provided by digital therapeutics, and the amount of healthcare cost reductions achieved by their use. Additionally, there is a growing inclination of pharmaceutical companies to integrate digital therapeutics with their drug product to offer adherence services along with their product. These are some of the factors responsible for the high share of this market segment.
Caregivers segment is expected to dominate the market
Based on the type of buyer, the B2C sales channel market is further segmented into patients and caregivers. The caregivers segment is expected to dominate the market, and register the highest CAGR during the forecast period. The high growth of this segment is attributed to company initiatives for the development of products specifically for caregivers and the fact that digital therapeutics help caregivers in better management of patients.
North America is expected to account for the largest market size during the forecast period
Geographically, the digital therapeutics market is segmented into North America, Europe, Asia-Pacific and the Rest of the World (RoW). In 2016, the North America is expected to dominate the market, followed by Europe. The market in North America is expected to grow at the highest CAGR during the forecast period. Factors such as the influx of new startups owing to increasing investments in the digital therapeutics field, gradually improving reimbursement structure for digital therapeutics solutions, and government initiatives to support technological developments and advancements in the field of digital therapeutics with a view to curb growing healthcare costs are driving the growth of digital therapeutics market in this region. However, stringent regulatory approval processes and unstable regulatory framework may restrict the growth of digital therapeutics market.
Key players in the Digital Therapeutics Market include Proteus Digital Health, Inc. (U.S.), Omada Health Inc. (U.S.), WellDoc Inc. (U.S.), Livongo Health (U.S.), Noom Inc. (U.S.), Ginger.io Inc. (U.S.), Propeller Health (U.S.), 2Morrow Inc. (U.S.), Canary Health Inc. (U.S.), Mango Health, Inc. (U.S.), and Physitrack Limited (U.K.). Click Therapeutics, Inc. (U.S.), Pear Therapeutics, Inc., (U.S.), Akili Interactive Labs, Inc. (U.S.) and Wellthy Therapeutics Pvt. Ltd (India) are some of the emerging players in this market.
Proteus Health is a leading provider of digital solutions based on ingestible computing. The company’s strengths lie in its innovative technology and focus on R&D activities for developing innovative products. The company majorly focuses on gaining investments for its development and growth. In this regard, in July 2014, the company secured a massive investment worth USD 172 million from a list of institutional investors; this investment was used for the manufacturing and development of its digital medicine products. Likewise, in May 2013, the company received an investment of USD 62.5 million from its investors. This investment was used to support the development of its novel digital medicine products
Omada Health, Inc. is a pioneer in the novel field of digital therapeutics. The company is gaining significant amount of investments to further enhance its digital program ‘Prevent’, which is an online program to fight prediabetes. In this regard, in September 2015, the company secured an investment of USD 48 million from its investors. Likewise, in April 2014, Omada secured an investment of USD 23 million from its investors. Omada’s digital therapeutics is gaining recognition from government bodies, which is helping the company to gain consumer faith in the product. For instance, in March 2015, Omada received recognition from the Centers for Disease Control and Prevention (CDC) for ‘Prevent’, signifying that it meets the evidence-based standards for CDC’s National Diabetes Prevention Program (DPP). This recognition has helped the company to convince patients, providers, and payers market this program to a wider audience
Recent Developments
- In Febuary 2016, Omada Health, Inc. launched a new version of its diabetes prevention program, Prevent. The new product includes additional features designed to meet the needs of underserved populations. This launch enabled the company to improve its product offerings and expand its customer base.
- In March 2016, WellDoc, Inc. entered into a strategic collaboration with LifeScan, Inc. (U.S .), a Johnson & Johnson (U.S.) company, to provide digital therapeutic solutions for patients with type 2 diabetes. As per this collaboration, WellDoc’s product Bluestar will be integrated with LifeScan’s products OneTouchVerio Fle Bluetooth Smart blood glucose monitoring system and OneTouch Revealmobile app. This collaboration enabled WellDoc to access Johnson and Johnson’s large patient base.
- In May 2016, Humana Inc. (U.S.), a leading health and well -being company in the U.S., made a strategic equity investment in Livongo Health. This investment enables the company to support its growth and accelerate the launch of new products and services in the market
- In April 2016, Proteus Digital Health, Inc. received a Series H financing worth USD 50 million. This enabled the company to expand its Digital Medicines platform.
Key Questions addressed by the report
- Where will all these developments take the industry in the mid to long term?
- Which are the recent contracts, partnership and agreements key players have signed?
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
Table of Contents
1 Digital Therapeutics Market, Introduction (Page No. - 18)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Market Stakeholders
2 Digital Therapeutics Market, Research Methodology (Page No. - 21)
2.1 Market Size Estimation
2.2 Market Breakdown and Data Triangulation
2.3 Key Data From Secondary Sources
2.4 Key Data From Primary Sources
2.5 Key Industry Insights
2.6 Assumptions for the Study
3 Digital Therapeutics Market, Executive Summary (Page No. - 29)
4 Digital Therapeutics Market, Premium Insights (Page No. - 35)
4.1 Market Overview
4.2 Market, By Application
4.3 Market for Preventive Applications
4.4 Market for Treatment/Care Applications
4.5 Market, By Sales Channel
4.6 Market for B2C Sales Channel, By Buyer
4.7 Market for B2B Sales Channel, By Buyer
4.8 Market: Geographic Snapshot
5 Digital Therapeutics Market, Overview (Page No. - 41)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Incidence of Preventable Chronic Diseases
5.2.1.2 Rising Focus on Preventive Healthcare
5.2.1.3 Technological Advancements
5.2.1.4 Need to Control Healthcare Costs
5.2.1.5 Significant Increase in Venture Capital Investments
5.2.1.6 Benefits Offered By Digital Therapeutics
5.2.1.6.1 Ability to Induce Behavioral Change
5.2.1.6.2 Improved Drug Adherence
5.2.1.6.3 Patient Convenience and User-Friendliness
5.2.2 Restraints
5.2.2.1 Lack of Awareness and Access to Digital Therapeutics Programs in Developing Countries
5.2.2.2 Patient Data Privacy Concerns
5.2.2.3 Resistance From Traditional Healthcare Providers
5.2.3 Opportunities
5.2.3.1 Emerging Markets Offer Significant Growth Opportunities
5.2.3.2 Large Undiagnosed and Untreated Population
5.2.3.3 Unexplored Therapeutic Applications
5.2.4 Challenges
5.2.4.1 Unfavorable Payment Models
5.2.4.2 Stringent Regulatory Guidelines
5.2.4.3 Reluctance Among Patients to Adopt Digital Therapeutics
6 Digital Therapeutics Market, Industry Insights (Page No. - 52)
6.1 Introduction
6.2 Porter’s Five Forces Analysis
6.2.1 Threat of New Entrants
6.2.2 Bargaining Power of Suppliers
6.2.3 Bargaining Power of Buyers
6.2.4 Threat of Substitutes
6.2.5 Intensity of Competitive Rivalry
6.3 Regulatory Requirements
6.3.1 Emerging Regulatory Framework for Digital Therapeutics
6.3.2 Health Information Portability and Accountability Act (HIPAA)
6.4 Venture Capital Investments
6.5 Pipeline Products
7 Digital Therapeutics Market, By Sales Channel (Page No. - 60)
7.1 Introduction
7.2 B2C
7.2.1 Caregivers
7.2.2 Patients
7.3 B2B
7.3.1 Providers
7.3.2 Payers
7.3.3 Pharmaceutical Companies
7.3.4 Employers
7.3.5 Other Buyers
8 Digital Therapeutics Market, By Type of Application (Page No. - 81)
8.1 Introduction
8.2 Preventive Applications
8.2.1 Prediabetes
8.2.2 Obesity
8.3 Treatment/Care-Related Applications
8.3.1 Diabetes
8.3.2 Central Nervous System (CNS) Disorders
8.3.3 Chronic Respiratory Diseases (CRD)
8.3.4 Musculoskeletal Disorders
8.3.5 Cardiovascular Diseases
8.3.6 Smoking Cessation
8.3.7 Medication Adherence
8.3.8 Other Applications
9 Digital Therapeutics Market, By Region (Page No. - 110)
9.1 Introduction
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Spain
9.3.5 Rest of Europe (RoE)
9.4 Asia-Pacific (APAC)
9.5 Rest of the World (RoW)
10 Competitive Landscape (Page No. - 152)
10.1 Overview
10.2 Competitive Situations and Trends
10.2.1 Partnerships, Collaborations, and Agreements
10.2.2 Investments
10.2.3 New Product Launches
10.2.4 Other Strategies
11 Company Profiles (Page No. - 160)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
11.1 Introduction
11.2 Proteus Digital Health, Inc.
11.3 Omada Health, Inc.
11.4 Welldoc, Inc.
11.5 Livongo Health
11.6 Noom Inc.
11.7 Ginger.Io, Inc.
11.8 Propeller Health
11.9 2morrow Inc.
11.10 Canary Health Inc.
11.11 Mango Health Inc.
*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.
12 Appendix (Page No. - 176)
12.1 Insights From Industry Experts
12.2 Discussion Guide
12.3 Other Developments, By Company, 2013–2016
12.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
12.5 Introducing RT: Real-Time Market Intelligence
12.6 Available Customizations
12.7 Related Reports
List of Tables (148 Tables)
Table 1 Increasing Incidence of Preventable Chronic Diseases: A Major Market Driver
Table 2 Lack of Awareness and Access to Digital Therapeutics Programs in Developing Countries: A Major Restraint for Market Growth
Table 3 Emerging Markets Offer Significant Growth Opportunities
Table 4 Stringent Regulatory Guidelines: A Major Challenge for Market Growth
Table 5 List of Venture Capital Investments in the Digital Therapeutics Market (2007-2016)
Table 6 List of Pipeline Products in the Market (2015-2021)
Table 7 Market Size, By Sales Channel, 2014-2021 (USD Million)
Table 8 Market Size for B2C Sales Channel, By Buyer, 2014-2021 (USD Million)
Table 9 Market Size for B2C Sales Channel, By Region, 2014-2021 (USD Million)
Table 10 North America: Market Size for B2C Sales Channel, By Country, 2014-2021 (USD Million)
Table 11 Europe: Market Size for B2C Sales Channel, By Country, 2014-2021 (USD Thousand)
Table 12 Market Size for Caregivers, By Region, 2014-2021 (USD Million)
Table 13 North America: Market Size for Caregivers, By Country, 2014-2021 (USD Million)
Table 14 Europe: Market Size for Caregivers, By Country, 2014-2021 (USD Thousand)
Table 15 Market Size for Patients, By Region, 2014-2021 (USD Thousand)
Table 16 North America: Market Size for Patients, By Country, 2014-2021 (USD Million)
Table 17 Europe: Market Size for Patients, By Country, 2014-2021 (USD Thousand)
Table 18 Market Size for B2B Sales Channel, By Buyer, 2014-2021 (USD Million)
Table 19 Market Size for B2B Sales Channel, By Region, 2014-2021 (USD Million)
Table 20 North America: Market Size for B2B Sales Channel, By Country, 2014-2021 (USD Million)
Table 21 Europe: Market Size for B2B Sales Channel, By Country, 2014-2021 (USD Million)
Table 22 Market Size for Providers, By Region, 2014-2021 (USD Million)
Table 23 North America: Market Size for Providers, By Country, 2014-2021 (USD Million)
Table 24 Europe: Market Size for Providers, By Country, 2014-2021 (USD Thousand)
Table 25 Market Size for Payers, By Region, 2014-2021 (USD Million)
Table 26 North America: Market Size for Payers, By Country, 2014-2021 (USD Million)
Table 27 Europe: Market Size for Payers, By Country, 2014-2021 (USD Million)
Table 28 Market Size for Pharmaceutical Companies, By Region, 2014-2021 (USD Thousand)
Table 29 North America: Market Size for Pharmaceutical Companies, By Country, 2014-2021 (USD Million)
Table 30 Europe: Market Size for Pharmaceutical Companies, By Country, 2014-2021 (USD Thousand)
Table 31 Market Size for Employers, By Region, 2014-2021 (USD Million)
Table 32 North America: Market Size for Employers, By Country, 2014-2021 (USD Million)
Table 33 Europe: Market Size for Employers, By Country, 2014-2021 (USD Thousand)
Table 34 Market Size for Other Buyers, By Region, 2014-2021 (USD Thousand)
Table 35 North America: Market Size for Other Buyers, By Country, 2014-2021 (USD Thousand)
Table 36 Europe: Market Size for Other Buyers, By Country, 2014-2021 (USD Thousand)
Table 37 Market Size, By Type of Application, 2014–2021 (USD Million)
Table 38 Market Size for Preventive Applications, 2014–2021 (USD Million)
Table 39 Market Size for Preventive Applications, By Region, 2014–2021 (USD Million)
Table 40 North America: Market Size for Preventive Applications, By Country, 2014–2021 (USD Million)
Table 41 Europe: Market Size for Preventive Applications, By Country, 2014–2021 (USD Million)
Table 42 Market Size for Prediabetes, By Region, 2014–2021 (USD Million)
Table 43 North America: Market Size for Prediabetes, By Country, 2014–2021 (USD Million)
Table 44 Europe: Market Size for Prediabetes, By Country, 2014–2021 (USD Thousand)
Table 45 Market Size for Obesity, By Region, 2014–2021 (USD Million)
Table 46 North America: Market Size for Obesity, By Country, 2014–2021 (USD Million)
Table 47 Europe: Market Size for Obesity, By Country, 2014–2021 (USD Million)
Table 48 Market Size for Treatment/Care-Related Applications, 2014–2021 (USD Million)
Table 49 Market Size for Treatment/Care-Related Applications, By Region, 2014–2021 (USD Million)
Table 50 North America: Market Size for Treatment/Care-Related Applications, By Country, 2014–2021 (USD Million)
Table 51 Europe: Market Size for Treatment/Care-Related Applications, By Country, 2014–2021 (USD Million)
Table 52 Market Size for Diabetes, By Region, 2014–2021 (USD Million)
Table 53 North America: Market Size for Diabetes, By Country, 2014–2021 (USD Million)
Table 54 Europe: Market Size for Diabetes, By Country, 2014–2021 (USD Million)
Table 55 Market Size for CNS Disorders, By Region, 2014–2021 (USD Thousand)
Table 56 North America: Market Size for CNS Disorders, By Country, 2014–2021 (USD Million)
Table 57 Europe: Market Size for CNS Disorders, By Country, 2014–2021 (USD Thousand)
Table 58 Market Size for Chronic Respiratory Diseases, By Region, 2014–2021 (USD Thousand)
Table 59 North America: Market Size for Chronic Respiratory Diseases, By Country, 2014–2021 (USD Million)
Table 60 Europe: Market Size for Chronic Respiratory Diseases, By Country, 2014–2021 (USD Thousand)
Table 61 Market Size for Musculoskeletal Disorders, By Region, 2014–2021 (USD Thousand)
Table 62 North America: Market Size for Musculoskeletal Disorders, By Country, 2014–2021 (USD Million)
Table 63 Europe: Market Size for Musculoskeletal Disorders, By Country, 2014–2021 (USD Thousand)
Table 64 Market Size for Cardiovascular Diseases, By Region, 2014–2021 (USD Million)
Table 65 North America: Market Size for Cardiovascular Diseases, By Country, 2014–2021 (USD Million)
Table 66 Europe: Market Size for Cardiovascular Diseases, By Country, 2014–2021 (USD Thousand)
Table 67 Market Size for Smoking Cessation, By Region, 2014–2021 (USD Million)
Table 68 North America: Market Size for Smoking Cessation, By Country, 2014–2021 (USD Million)
Table 69 Europe: Market Size for Smoking Cessation, By Country, 2014–2021 (USD Million)
Table 70 Market Size for Medication Adherence, By Region, 2014–2021 (USD Thousand)
Table 71 North America: Market Size for Medication Adherence, By Country, 2014–2021 (USD Million)
Table 72 Europe: Market Size for Medication Adherence, By Country, 2014–2021 (USD Thousand)
Table 73 Market Size for Other Applications, By Region, 2014–2021 (USD Thousand)
Table 74 North America: Market Size for Other Applications, By Country, 2014–2021 (USD Million)
Table 75 Europe: Market Size for Other Applications, By Country, 2014–2021 (USD Thousand)
Table 76Market Size, By Region, 2014-2021 (USD Million)
Table 77 North America: Market Size, By Country, 2014-2021 (USD Million)
Table 78 North America: Market Size, By Application, 2014–2021 (USD Million)
Table 79 North America: Market Size for Preventive Applications, By Disorder, 2014–2021 (USD Million)
Table 80 North America: Market Size for Treatment/Care-Based Applications, 2014–2021 (USD Million)
Table 81 North America: Market Size, By Sales Channel, 2014-2021 (USD Million)
Table 82 North America: Market Size for B2C Sales Channel, By Buyer, 2014-2021 (USD Million)
Table 83 North America: Market Size for B2B Sales Channel, By Buyer, 2014-2021 (USD Million)
Table 84 U.S.: Market Size, By Application, 2014–2021 (USD Million)
Table 85 U.S.: Market Size for Preventive Applications, By Disorder, 2014–2021 (USD Million)
Table 86 U.S.: Market Size for Treatment/Care-Based Applications, 2014–2021 (USD Million)
Table 87 U.S.: Market Size, By Sales Channel, 2014-2021 (USD Million)
Table 88 U.S.: Market Size for B2C Sales Channel, By Buyer, 2014-2021 (USD Million)
Table 89 U.S.: Market Size for B2B Sales Channel, By Buyer, 2014-2021 (USD Million)
Table 90 Canada: Market Size, By Application, 2014–2021 (USD Million)
Table 91 Canada: Market Size for Preventive Applications, By Disorder, 2014–2021 (USD Million)
Table 92 Canada: Market Size for Treatment/Care-Based Applications, 2014–2021 (USD Million)
Table 93 Canada: Market Size, By Sales Channel, 2014-2021 (USD Million)
Table 94 Canada: Market Size for B2C Sales Channel, By Buyer, 2014-2021 (USD Million)
Table 95 Canada: Market Size for B2B Sales Channel, By Buyer, 2014-2021 (USD Thousand)
Table 96 Europe: Market Size, By Country, 2014-2021 (USD Million)
Table 97 Europe: Market Size, By Application, 2014–2021 (USD Million)
Table 98 Europe: Market Size for Preventive Applications, By Disorder, 2014–2021 (USD Million)
Table 99 Europe: Market Size for Treatment/Care-Based Applications, 2014–2021 (USD Million)
Table 100 Europe: Market Size, By Sales Channel, 2014-2021 (USD Million)
Table 101 Europe: Market Size for B2C Sales Channel, By Buyer, 2014-2021 (USD Million)
Table 102 Europe: Market Size for B2B Sales Channel, By Buyer, 2014-2021 (USD Million)
Table 103 Germany: Market Size, By Application, 2014–2021 (USD Million)
Table 104 Germany: Market Size for Preventive Applications, By Disorder, 2014–2021 (USD Million)
Table 105 Market Size for Treatment/Care-Based Applications, 2014–2021 (USD Million)
Table 106 Germany: Market Size, By Sales Channel, 2014-2021 (USD Million)
Table 107 Germany: Market Size for B2C Sales Channel, By Buyer, 2014-2021 (USD Million)
Table 108 Germany: Market Size for B2B Sales Channel, By Buyer, 2014-2021 (USD Million)
Table 109 U.K.: Market Size, By Application, 2014–2021 (USD Million)
Table 110 U.K.: Market Size for Preventive Applications, By Disorder, 2014–2021 (USD Million)
Table 111 U.K.: Market Size for Treatment/Care-Based Applications, 2014–2021 (USD Thousand)
Table 112 U.K.: Market Size, By Sales Channel, 2014-2021 (USD Million)
Table 113 U.K.: Market Size for B2C Sales Channel, By Buyer, 2014-2021 (USD Million)
Table 114 U.K.: Digital Therapeutics Market Size for B2B Sales Channel, By Buyer, 2014-2021 (USD Thousand)
Table 115 France: Digital Therapeutics Market Size, By Application, 2014–2021 (USD Million)
Table 116 France: Digital Therapeutics Market Size for Preventive Applications, By Disorder, 2014–2021 (USD Million)
Table 117 France: Digital Therapeutics Market Size for Treatment/Care-Based Applications, 2014–2021 (USD Thousand)
Table 118 France: Digital Therapeutics Market Size, By Sales Channel, 2014-2021 (USD Million)
Table 119 France: Digital Therapeutics Market Size for B2C Sales Channel, By Buyer, 2014-2021 (USD Million)
Table 120 France: Digital Therapeutics Market Size for B2B Sales Channel, By Buyer, 2014-2021 (USD Thousand)
Table 121 Spain: Digital Therapeutics Market Size, By Application, 2014–2021 (USD Million)
Table 122 Spain: Digital Therapeutics Market Size for Preventive Applications, By Disorder, 2014–2021 (USD Thousand)
Table 123 Spain: Digital Therapeutics Market Size for Treatment/Care-Based Applications, 2014–2021 (USD Thousand)
Table 124 Spain: Digital Therapeutics Market Size, By Sales Channel, 2014-2021 (USD Thousand)
Table 125 Spain: Digital Therapeutics Market Size for B2C Sales Channel, By Buyer, 2014-2021 (USD Thousand)
Table 126 Spain: Digital Therapeutics Market Size for B2B Sales Channel, By Buyer, 2014-2021 (USD Thousand)
Table 127 RoE: Digital Therapeutics Market Size, By Application, 2014–2021 (USD Million)
Table 128 RoE: Digital Therapeutics Market Size for Preventive Applications, By Disorder, 2014–2021 (USD Million)
Table 129 RoE: Digital Therapeutics Market Size for Treatment/Care-Based Applications, 2014–2021 (USD Thousand)
Table 130 RoE: Digital Therapeutics Market Size, By Sales Channel, 2014-2021 (USD Thousand)
Table 131 RoE: Digital Therapeutics Market Size for B2C Sales Channel, By Buyer, 2014-2021 (USD Thousand)
Table 132 RoE: Digital Therapeutics Market Size for B2B Sales Channel, By Buyer, 2014-2021 (USD Thousand)
Table 133 APAC: Digital Therapeutics Market Size, By Application, 2014–2021 (USD Million)
Table 134 APAC: Digital Therapeutics Market Size for Preventive Applications, By Disorder, 2014–2021 (USD Million)
Table 135 APAC: Digital Therapeutics Market Size for Treatment/Care-Based Applications, 2014–2021 (USD Thousand)
Table 136 APAC: Digital Therapeutics Market Size, By Sales Channel, 2014-2021 (USD Million)
Table 137 APAC: Digital Therapeutics Market Size for B2C Sales Channel, By Buyer, 2014-2021 (USD Million)
Table 138 APAC: Digital Therapeutics Market Size for B2B Sales Channel, By Buyer, 2014-2021 (USD Thousand)
Table 139 RoW: Digital Therapeutics Market Size, By Application, 2014–2021 (USD Million)
Table 140 RoW: Digital Therapeutics Market Size for Preventive Applications, By Disorder, 2014–2021 (USD Million)
Table 141 RoW: Digital Therapeutics Market Size for Treatment/Care-Based Applications, 2014–2021 (USD Thousand)
Table 142 RoW: Digital Therapeutics Market Size, By Sales Channel, 2014-2021 (USD Million)
Table 143 RoW: Digital Therapeutics Market Size for B2C Sales Channel, By Buyer, 2014-2021 (USD Thousand)
Table 144 RoW: Digital Therapeutics Market Size for B2B Sales Channel, By Buyer, 2014-2021 (USD Thousand)
Table 145 Partnerships, Collaborations, and Agreements, 2016
Table 146 Investments, 2015–2016
Table 147 New Product Launches, 2014–2016
Table 148 Other Strategies, 2013–2016
List of Figures (36 Figures)
Figure 1 Research Design
Figure 2 Market Size Estimation: Bottom-Up Approach
Figure 3 Market Size Estimation: Top-Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Data Triangulation Methodology
Figure 6 Digital Therapeutics for Preventive Applications to Register High Growth During the Forecast Period
Figure 7 Digital Therapeutics Market for Preventive Applications, 2016 vs 2021
Figure 8 Digital Therapeutics Market for Treatment/Care Applications, 2016 vs 2021
Figure 9 Digital Therapeutics Market, By Sales Channel: B2B Sales Channel Expected to Dominate the Market in 2016
Figure 10 Caregivers Segment to Register Significant Growth During the Forecast Period
Figure 11 Payers to Dominate the Digital Therapeutics Market During the Forecast Period
Figure 12 Digital Therapeutics Market, By Region: North America is Expected to Register the Highest Growth in the Forecast Period
Figure 13 Venture Capital Investments and Supporting Government Initiatives: Major Factors Driving Market Growth
Figure 14 Solutions for Treatment/Care Segment to Dominate the Digital Therapeutics Market in 2016
Figure 15 Obesity Segment to Register Highest Growth in the Forecast Period
Figure 16 Diabetes to Dominate the Market By 2021
Figure 17 B2B Segment to Form the Largest Sales Channel in 2016
Figure 18 Caregivers to Be the Largest Segment of the Market in 2016
Figure 19 Payers to Command the Largest Market Share in 2016
Figure 20 U.S. to Witness Highest Market Growth During the Forecast Period
Figure 21 Digital Therapeutics Market: Drivers, Restraints, Opportunities, and Challenges
Figure 22 Porter’s Five Forces Analysis
Figure 23 Digital Therapeutics Market Segmentation, By Sales Channel
Figure 24 B2B Segment to Dominate the Digital Therapeutics Market, By Sales Channel, in 2016
Figure 25 Caregivers to Dominate the Digital Therapeutics Market, By B2C Sales Channel, in 2016
Figure 26 Payers to Dominate the Digital Therapeutics Market, By B2B Sales Channel, in 2016
Figure 27 Digital Therapeutics Market, By Type of Application
Figure 28 Treatment/Care-Related Applications to Dominate the Digital Therapeutics Market in 2016
Figure 29 Obesity to Dominate the Digital Therapeutics Application Market in 2016
Figure 30 Diabetes to Dominate the Digital Therapeutics Application Market in 2016
Figure 31 North America to Dominate the Digital Therapeutics Market in 2016
Figure 32 North America: Digital Therapeutics Market Overview
Figure 33 Key Players Adopted Organic as Well as Inorganic Growth Strategies Between 2013 and 2016
Figure 34 Market Evolution Framework
Figure 35 Battle for Market Share: Partnerships, Collaborations, and Agreements—The Key Growth Strategy Adopted By Market Players
Figure 36 Product Portfolio Mix for the Top 5 Players
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Digital Therapeutics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Digital Therapeutics Market